Yestar Healthcare Holdings Co (HKSE:02393) Other Financing: HK$-77 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Yestar Healthcare Holdings Co Other Financing?

Yestar Healthcare Holdings Co HKSE:02393 +4.55% Other Financing is HK$-77 Mil as of Jun. 2026. The stock has 4 warning signs investors should review.

Yestar Healthcare Holdings Co's Other Financing for the six months ended in Jun. 2026 was HK$-33 Mil.

Yestar Healthcare Holdings Co's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-77 Mil.

Yestar Healthcare Holdings Co Other Financing Historical Data

* Premium members only.

The historical data trend for Yestar Healthcare Holdings Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yestar Healthcare Holdings Co Other Financing Chart

Yestar Healthcare Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -490.30 -296.20 -238.91 -627.37 -78.54

Yestar Healthcare Holdings Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.78 -582.93 -34.95 -44.33 -32.68

Yestar Healthcare Holdings Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$-77 Mil mean?
Yestar Healthcare Holdings Co (HKSE:02393) has a Other Financing of HK$-77 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Yestar Healthcare Holdings Co and its competitors.
Is Yestar Healthcare Holdings Co's Other Financing too high?
Yestar Healthcare Holdings Co's current Other Financing is HK$-77 Mil.
How does Yestar Healthcare Holdings Co's Other Financing compare to ABT and SYK?
Yestar Healthcare Holdings Co's Other Financing of HK$-77 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Yestar Healthcare Holdings Co and its competitors. Yestar Healthcare Holdings Co's current Other Financing is HK$-77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yestar Healthcare Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Yestar Healthcare Holdings Co (HKSE:02393) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.07 — trading 38% above its estimated fair value. The current Other Financing is HK$-77 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Yestar Healthcare Holdings Co (HKSE:02393), the current Other Financing is HK$-77 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yestar Healthcare Holdings Co Business Description

Address No. 1, Lane 388, Kang’an Road, Room 1210-1213, 12th Floor, Building T1, Pudong New District, Shanghai, CHN
Yestar Healthcare Holdings Co Ltd is engaged in the manufacture, distribution, and sale of medical imaging products, distribution of In Vitro Diagnostic (IVD) products, and manufacture and sale of dental films. The Group has two reportable operating segments: Imaging printing products segment, which includes the manufacture and sale of colour photographic paper, industrial NDT x-ray films and PWB films, and trading of imaging equipment; and Medical products and equipment segment, which generates maximum revenue and includes manufacture and sale of medical dry films, medical wet films and dental films, and sale of medical equipment and diagnostic reagents. The Group operates its business in Mainland China.